TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 1,803 shares of the firm’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $54.86, for a total value of $98,912.58. Following the transaction, the senior vice president now directly owns 11,647 shares of the company’s stock, valued at approximately $638,954.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of TESARO Inc (TSRO) traded down $1.91 during trading hours on Wednesday, hitting $62.69. The stock had a trading volume of 819,305 shares, compared to its average volume of 1,120,000. TESARO Inc has a one year low of $52.20 and a one year high of $171.80. The firm has a market cap of $3,410.00, a P/E ratio of -6.83 and a beta of 1.40. The company has a debt-to-equity ratio of 1.75, a current ratio of 4.74 and a quick ratio of 4.39.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). The business had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $51.78 million. TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. research analysts expect that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Toronto Dominion Bank lifted its holdings in shares of TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,130 shares in the last quarter. Commonwealth Equity Services Inc acquired a new position in shares of TESARO in the third quarter worth $222,000. Crossmark Global Holdings Inc. acquired a new position in shares of TESARO in the third quarter worth $230,000. CIBC Asset Management Inc acquired a new position in shares of TESARO in the third quarter worth $234,000. Finally, Exane Derivatives increased its stake in shares of TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,123 shares during the last quarter.
A number of equities research analysts have issued reports on the company. Leerink Swann raised TESARO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, November 15th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of TESARO in a research note on Monday, November 20th. Cowen reduced their price objective on TESARO from $125.00 to $80.00 and set a “market perform” rating on the stock in a research note on Tuesday, January 2nd. Piper Jaffray Companies restated a “hold” rating and set a $80.00 price objective on shares of TESARO in a research note on Tuesday, January 2nd. Finally, Argus set a $154.00 price target on TESARO and gave the stock a “buy” rating in a research note on Tuesday, November 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $133.39.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://ledgergazette.com/2018/03/14/tesaro-inc-tsro-svp-sells-98912-58-in-stock.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.